# US 2024/0199631 A1 · Synthesis of human serum albumin conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199631 A1
- Document ID: US20240199631A1
- Status: Published application
- Kind: A1
- Application number: 18/522,750
- Filed: 2023-11-29
- Published: 2024-06-20
- Earliest claimed: 2022-12-01
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: Jun Xie; Yuelong Ma; David Horne
- Web page: https://patentgrep.com/patent/US20240199631A1

## CPC

- C07D 491/22: in which the condensed system contains four or more hetero rings
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61P 35/00: Antineoplastic agents
- C07K 14/765: Serum albumin, e.g. HSA
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein, inter alia, is a method of conjugating of human serum Albumin (HSA) to SN38.

## Claims

### Claim 1

A method of making succinyl-(C20—OH)SN38, said method comprising combining SN38, (diazabicyclo[5.4.0]undec-7-ene (DBU) and succinic anhydride into a reaction vessel, thereby producing succinyl-(C20—OH)SN38,
wherein SN38 has the structure:
and
wherein succinyl-(C20—OH)SN38 has the structure:

### Claim 2 (depends on 1)

The method of claim 1, wherein the reaction vessel comprises dimethylformamide (DMF) as a solvent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the yield of succinyl-(C20—OH)SN38 is greater than 65%.

### Claim 4 (depends on 3)

The method of claim 3, wherein the yield of succinyl-(C20—OH)SN38 is greater than 80%.

### Claim 5 (depends on 7)

The method of claim 7, wherein the yield of succinyl-(C20—OH)SN38 is greater than 90%.

### Claim 6 (depends on 1)

The method of claim 1, wherein a molar ratio of SN38 to DBU to succinic anhydride is 1 to at least 1.1 to at least 1:1.

### Claim at position 7

7-29. (canceled)

### Claim 30 (depends on 1)

The method of claim 1, further comprising isolating the succinyl-(C20—OH)SN38 from the reaction mixture after producing succinyl-(C20—OH)SN38, thereby forming an isolated succinyl-(C20—OH)SN38.

### Claim 31 (depends on 30)

The method of claim 30, wherein the succinyl-(C20—OH)SN38 is isolated from the reaction mixture as a precipitant.

### Claim 32 (depends on 30)

The method of claim 30 er 31, further comprising contacting the isolated succinyl-(C20—OH)SN38 with dicyclohexyl carbodiimide (DCC) in the presence of N-hydroxysuccinimide (NHS), thereby forming an activated succinyl-(C20—OH)SN38.

### Claim 33 (depends on 32)

The method of claim 32, further comprising contacting the activated succinyl-(C20—OH)SN38 with human serum albumin (HSA), thereby forming an HSA-SN38 conjugate having the formula:

### Claim 34 (depends on 33)

The method of claim 33, wherein the reaction produces a population of SN38-HSA conjugates, wherein the population comprises a SN38-HSA conjugate having a SN38 to HSA ratio of at least one of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 9:1, 10:1, 11:1 or 12:1.

### Claim at position 13

35-45. (canceled)

### Claim 46

A population of SN38-HSA conjugates, wherein the population comprises a SN38-HSA conjugate having a SN38 to HSA ratio of at least one of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 9:1, 10:1, 11:1 or 12:1.

### Claim at position 15

47-57. (canceled)
